Cytek Common Stock Total Equity from 2010 to 2026
| CTKB Stock | USD 4.18 0.18 4.13% |
Common Stock Total Equity | First Reported 2010-12-31 | Previous Quarter 155.2 K | Current Value 83.9 K | Quarterly Volatility 54.4 K |
Check Cytek Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cytek Biosciences' main balance sheet or income statement drivers, such as Tax Provision of 386.4 K, Net Interest Income of 12.5 M or Interest Income of 12.5 M, as well as many indicators such as Price To Sales Ratio of 4.62, Dividend Yield of 0.0 or PTB Ratio of 2.02. Cytek financial statements analysis is a perfect complement when working with Cytek Biosciences Valuation or Volatility modules.
Cytek | Common Stock Total Equity | Build AI portfolio with Cytek Stock |
Analyzing Cytek Biosciences's Common Stock Total Equity over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Common Stock Total Equity has evolved provides context for assessing Cytek Biosciences's current valuation and future prospects.
Latest Cytek Biosciences' Common Stock Total Equity Growth Pattern
Below is the plot of the Common Stock Total Equity of Cytek Biosciences over the last few years. It is the total value of common stock equity held by shareholders, representing their ownership interest in the company. Cytek Biosciences' Common Stock Total Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cytek Biosciences' overall financial position and show how it may be relating to other accounts over time.
| Common Stock Total Equity | 10 Years Trend |
|
Common Stock Total Equity |
| Timeline |
Cytek Common Stock Total Equity Regression Statistics
| Arithmetic Mean | 59,007 | |
| Geometric Mean | 39,757 | |
| Coefficient Of Variation | 92.28 | |
| Mean Deviation | 48,951 | |
| Median | 21,000 | |
| Standard Deviation | 54,449 | |
| Sample Variance | 3B | |
| Range | 134.2K | |
| R-Value | 0.79 | |
| Mean Square Error | 1.2B | |
| R-Squared | 0.62 | |
| Significance | 0.0002 | |
| Slope | 8,509 | |
| Total Sum of Squares | 47.4B |
Cytek Common Stock Total Equity History
About Cytek Biosciences Financial Statements
Cytek Biosciences stakeholders use historical fundamental indicators, such as Cytek Biosciences' Common Stock Total Equity, to determine how well the company is positioned to perform in the future. Although Cytek Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Cytek Biosciences' assets and liabilities are reflected in the revenues and expenses on Cytek Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Cytek Biosciences. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Common Stock Total Equity | 155.2 K | 83.9 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cytek Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cytek Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cytek Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cytek Biosciences Stock:Check out the analysis of Cytek Biosciences Correlation against competitors. For information on how to trade Cytek Stock refer to our How to Trade Cytek Stock guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytek Biosciences. Projected growth potential of Cytek fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Cytek Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 0.735 | Earnings Share (0.11) | Revenue Per Share | Quarterly Revenue Growth 0.015 | Return On Assets |
Investors evaluate Cytek Biosciences using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Cytek Biosciences' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Cytek Biosciences' market price to deviate significantly from intrinsic value.
It's important to distinguish between Cytek Biosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cytek Biosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Cytek Biosciences' market price signifies the transaction level at which participants voluntarily complete trades.